🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Suzhou
Clinical trial register · China

Clinical Trials in Suzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Soochow University115 Second Affiliated Hospital of Soochow University16 Capital Medical University9 Novartis Pharmaceuticals8 Takeda8
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Suzhou

421 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
By invitation
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
NCT06544109Acute Promyelocytic Leukemia
The First Affiliated Hospital of Soochow University
Phase 2/3
98
Suzhou
2023-08-01
Not yet open
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
NCT05931757Philadelphia-Positive ALL
The First Affiliated Hospital of Soochow University
Phase 2
22
Suzhou
2023-07-01
Recruiting
Venetoclax Combined With Azactidine in the Treatment of ALAL
NCT05901974Acute Leukemia of Ambiguous Lineage
Sheng-Li Xue, MD
Phase 2
23
Suzhou
2023-07-01
By invitation
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
NCT06468943Effects of Chemotherapy, Safety Issues
The First Affiliated Hospital of Soochow University
Phase 2
20
Suzhou
2023-07-01
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839Multiple Myeloma
GlaxoSmithKline
Phase 1/2
123
Suzhou
2023-06-14
Recruiting
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
NCT06018363Brain Gliomas, High-Grade Gliomas, GBM
Dushu Lake Hospital Affiliated to Soochow University
Phase 1/2
25
Suzhou
2023-06-01
By invitation
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
NCT06186804cGvHD
Abbisko Therapeutics Co, Ltd
Phase 2
64
Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou
2023-05-30
Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage
NCT07088250Cerebrovascular Disorders, Intracranial Hemorrhages, Intracranial Hemorrhage, Intracerebral Haemorrhage
The Second Hospital of Anhui Medical University
Not applicable
264
Anqing, Fuyang, Hefei, Huainan, Lu'an, Suzhou, Harbin, Kaifeng
2023-05-06
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Recruiting
REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry
NCT05728775Anesthesia, Surgery-Complications
Nanfang Hospital, Southern Medical University
Phase 4
7,188
Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan
2023-04-03
Recruiting
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05768529Relapsed or Refractory Non-Hodgkin's Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2
100
Changsha, Suzhou
2023-03-28
Recruiting
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
NCT05772273Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Not applicable
43
Suzhou
2023-03-15
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
By invitation
FMT in Transplant-related Gastrointestinal Mucositis
NCT07622849Transplant-related Gastrointestinal Mucositis
The First Affiliated Hospital of Soochow University
Observational
20
Suzhou
2023-03-01
Recruiting
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
NCT05805098Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2/3
60
Suzhou
2023-03-01
Recruiting
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
NCT05824169Spinal Muscular Atrophy
GeneCradle Inc
Phase 1/2
18
Beijing, Shenyang, Suzhou
2023-02-25
Recruiting
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
NCT05641259Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
198
Nanchang, Suzhou, Zhengzhou
2023-02-14
Recruiting
Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
NCT06790797Lung Cancer, Esophageal Cancer
Zhao Jun
Observational
50
Suzhou
2023-02-12
Active, closed
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
NCT05546866Non-small Cell Lung Cancer
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Recruiting
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
NCT05872724Cervical Cancer
Suzhou Municipal Hospital
Phase 2
32
Suzhou
2023-01-16
Active, closed
Adult Spinal Muscular Atrophy (SMA) China Registry
NCT05618379Muscular Atrophy, Spinal
Biogen
Observational
200
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Nanchang
2023-01-06
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
213
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Recruiting
Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases
NCT05965128Respiratory Infectious Diseases
Huashan Hospital
Observational
1,255
Lanzhou, Harbin, Hohhot, Suzhou, Xuzhou, Shenyang, Jinan, Jining
2022-12-01
Recruiting
Intelligent Diagnosis and Treatment Model for Insomnia Disorder
NCT06375447Insomnia
Xuanwu Hospital, Beijing
Observational
16,000
Beijing, Changchun, Chengdu, Suzhou
2022-12-01
Recruiting
Construction of a Database for TMA
NCT05634928Thrombotic Microangiopathies
The First Affiliated Hospital of Soochow University
Observational
500
Suzhou
2022-12-01
Recruiting
Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
NCT05661786Chronic Hepatitis b
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
4,500
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2022-12
Recruiting
Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or Severe Degenerative Mitral Regurgitation
NCT05655897Mitral Regurgitation, Degenerative Mitral Valve Disease
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
120
Suzhou
2022-11-24
Recruiting
Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community
NCT05349955Type 2 Diabetes, Cardiovascular Complication, Diabetic Kidney Disease
Shanghai Zhongshan Hospital
Not applicable
5,600
Suzhou
2022-11-21
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
Pfizer
Phase 3
1,116
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Recruiting
Construction of a Database for TTP
NCT05571774TTP - Thrombotic Thrombocytopenic Purpura
The First Affiliated Hospital of Soochow University
Observational
500
Suzhou
2022-10-20
Active, closed
Efficacy and Safety of Trabecular Meshwork Microstent Drainage System ( MicroCOGO )
NCT06741774Open-angle Glaucoma, Cataract
Healthguard Biomed
Not applicable
207
Suzhou
2022-10-19
Recruiting
CAV Regimen for R/R AML
NCT05657639Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
68
Suzhou
2022-10-01
Recruiting
CAV Regimen for R/R Ph- B-ALL
NCT05657652Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Not applicable
36
Suzhou
2022-10-01
Recruiting
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368Hypereosinophilic Syndrome
GlaxoSmithKline
Phase 3
109
Beijing, Changsha, Guangzhou, Harbin, Nanchang, Shanghai, Suzhou, Wuhan
2022-09-06
Recruiting
Olverembatinib for FGFR1-rearranged Neoplasms
NCT05521204Myeloproliferative Neoplasm, Acute Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
20
Suzhou
2022-09-01
Recruiting
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
NCT05940961ALL, MRD-positive, Hematopoietic Stem Cell Transplantation
Sheng-Li Xue, MD
Phase 2
42
Suzhou
2022-08-01
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
NCT05899049Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Recruiting
Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China
NCT05610566Mitral Regurgitation
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
110
Suzhou
2022-07-06
Recruiting
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
NCT05404906Acute Myeloid Leukemia (AML) in Remission
The First Affiliated Hospital of Soochow University
Phase 2/3
124
Suzhou
2022-06-25
Active, closed
Observational Study in Multiple System Atrophy
NCT05453058Multiple System Atrophy
H. Lundbeck A/S
Observational
90
Beijing, Changsha, Chengdu, Shanghai, Suzhou
2022-06-25
Active, closed
Intracranial Arterial Stenosis in Young Patients
NCT05844176Intracranial Arterial Stenosis
Capital Medical University
Observational
500
Suzhou, Shijiazhuang, Beijing, Zhengzhou
2022-06-01
Active, closed
Cohort Construction and Prognostic Model Construction for Multiple Myeloma
NCT06366802Multiple Myeloma
The First Affiliated Hospital of Soochow University
Observational
1,000
Suzhou
2022-05-03
Recruiting
Urine and Ultrasound Screening for Kidney Disease in Children
NCT06018831Kidney Diseases, Diagnostic Techniques, Ultrasound, Urinalysis
Children's Hospital of Fudan University
Not applicable
13,000
Nantong, Suzhou
2022-04-12
Recruiting
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
NCT05376111T-cell Acute Lymphoblastic Leukemia, Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
28
Suzhou
2022-04-01
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
Active, closed
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05201248B-Cell Non-Hodgkin Lymphoma
Genmab
Phase 1/2
49
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Xuzhou
2022-03-10
Active, closed
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
NCT05177731AML, Adult, Chemotherapy Effect
Chen Suning
Phase 3
188
Suzhou
2022-03-01
Recruiting
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
NCT05566054Acute Monocytic Leukemia, Newly Diagnosed
The First Affiliated Hospital of Soochow University
Phase 2
92
Suzhou
2022-03-01
Recruiting
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
NCT05263206Pruritus
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Active, closed
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
NCT05353816End-stage Heart Failure
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
50
Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou
2022-01-26
Recruiting
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 2
100
Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang
2022-01-26
Recruiting
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
NCT06760260Acute Myeloid Leukemia (AML)
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1
7
Suzhou
2022-01-26
Active, closed
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT05144243Acute Myeloid Leukemia (AML)
AbbVie
Phase 4
44
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang
2022-01-06
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ascentage Pharma Group Inc.
Phase 2
75
Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou
2021-12-28
Active, closed
TACS Intervention for Methamphetamine Addiction
NCT06288997Methamphetamine Use Disorder
Shanghai Mental Health Center
Not applicable
70
Beijing, Wuhan, Nanjing, Suzhou, Deyang
2021-11-21
Active, closed
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
NCT05013190Multiple Myeloma
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
Active, closed
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
NCT05485948Polycythemia Vera
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Active, closed
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT05029141Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML
The First Affiliated Hospital of Soochow University
Phase 2
21
Suzhou
2021-09-01
Recruiting
Light Therapy in Parkinson's Disease
NCT06129942Parkinson Disease, Sleep Disorder, Circadian Rhythm Disorders
Second Affiliated Hospital of Soochow University
Not applicable
50
Suzhou
2021-09-01
Active, closed
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, Female
Wenjun Cheng
Phase 2
56
Huai'an, Nanjing, Suzhou, Wuxi, Yancheng
2021-08-24
By invitation
Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
NCT06101940Myotonic Dystrophy 1
Huashan Hospital
Observational
1,000
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou
2021-08-01
Active, closed
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT06868654Multiple Myeloma
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
By invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Suzhou, Tianjin, Wenzhou
2021-07-27
Active, closed
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
NCT04944043Chronic Graft Versus Host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
45
Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin
2021-06-25
Active, closed
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
NCT04900350Myelodysplastic Syndrome
Akeso
Phase 1/2
136
Suzhou
2021-06-18
Recruiting
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
NCT04853342Non-small Cell Lung Carcinoma
Allist Pharmaceuticals, Inc.
Phase 3
318
Suzhou
2021-06-07
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Recruiting
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
NCT04588922Hematologic Malignancies
Sellas Life Sciences Group
Phase 1/2
160
Bengbu, Hefei, Chongqing, Guangzhou, Baoding, Zhengzhou, Suzhou, Nanchang
2021-05-10
Recruiting
Study of GC101 TIL in Brain Glioma (Soochow2)
NCT04943913Glioma
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
50
Suzhou
2021-05-06
Active, closed
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
NCT04683003Thrombotic Thrombocytopenic Purpura (TTP)
Takeda
Phase 3
77
Beijing, Wuhan, Suzhou, Tianjin
2021-04-14
Active, closed
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
NCT04562870Myelofibrosis
Karyopharm Therapeutics Inc
Phase 2
112
Beijing, Wuhan, Nantong, Suzhou, Changchun, Hangzhou
2021-03-17
Recruiting
Efficacy and Safety of Auto-FMT in Preventing aGVHD
NCT04745221Graft Versus Host Disease, Acute
The First Affiliated Hospital of Soochow University
Not applicable
100
Suzhou
2021-03-01
Active, closed
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
NCT04644575Hemophilia A
Bioverativ, a Sanofi company
Phase 3
261
Beijing, Guangzhou, Hangzhou, Jinan, Kunming, Lanzhou, Suzhou
2021-02-23
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
510
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
2021-02-01
Active, closed
A Study of Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon
NCT04826705Drug-coated Balloon, Femoropopliteal Artery Occlusion, Angioplasty
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
2,000
Wuhan, Beijing, Chengdu, Hangzhou, Qingdao, Shanghai, Suzhou
2021-02-01
Active, closed
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 1/2
181
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Qingdao, Xi’an
2021-01-04
Recruiting
Durg Coated Balloon Angioplasty in Infrapopliteal Lesions
NCT05620095Arteriosclerosis, Peripheral Artery Disease, Chronic Limb Threatening Ischemia
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
1,000
Beijing, Wuhan, Suzhou, Qingdao, Shanghai, Chengdu, Hangzhou
2020-12-01
Recruiting
Relationship Between "FODMAPs" and "GVHD"
NCT04660487Graft Versus Host Disease
The First Affiliated Hospital of Soochow University
Observational
100
Suzhou
2020-12-01
Active, closed
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
NCT04512235AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 3
281
Beijing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wenzhou, Wuhan
2020-11-03
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
Amgen
Phase 3
238
Beijing, Guiyang, Hunan, Jinan, Shanghai, Suzhou, Tianjin, Xi'an
2020-10-15
Recruiting
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
NCT04501120Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Ascentage Pharma Group Inc.
Phase 1/2
682
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai
2020-09-28
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
AbbVie
Phase 3
531
Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou
2020-09-10
Active, closed
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
NCT05395533CD20-positive B-cell Non-Hodgkin Lymphoma
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1
147
Beijing, Guangzhou, Zhengzhou, Suzhou, Tianjin
2020-09-08
Active, closed
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2/3
501
Nanjing, Suzhou, Huangpu, Xuhui, Chengdu, Hangzhou
2020-09-03
Recruiting
The Risk Factors of Cardiovascular Disease in Elderly Diabetic Patients: A Prospective Cohort Study
NCT04544527Diabetes Mellitus, Cardiovascular Diseases, Complication Diabetic
Shanghai Zhongshan Hospital
Observational
10,000
Suzhou
2020-09-01
Active, closed
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
NCT04547049Leukemia, MDS
First Affiliated Hospital of Zhejiang University
Phase 3
232
Changsha, Chongqing, Hangzhou, Nanjing, Ningbo, Suzhou
2020-09-01
Active, closed
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
NCT04285086Essential Thrombocythemia
PharmaEssentia
Phase 3
174
Beijing, Chongqing, Guangzhou, Wuhan, Suzhou, Shenyang, Xi'an, Jinan
2020-08-25
Active, closed
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
NCT04233346Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Otsuka Beijing Research Institute
Phase 2
93
Hefei, Guangzhou, Wuhan, Changsha, Suzhou, Shenyang, Jinan, Taiyuan
2020-07-09
Recruiting
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
NCT04275518Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Ascentage Pharma Group Inc.
Phase 1
102
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Nanchang, Changchun
2020-07-06
Active, closed
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
NCT05470777B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
37
Suzhou
2020-01-19
Recruiting
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05182957Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2
31
Suzhou
2020-01-01
Active, closed
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317Non-muscle Invasive Bladder Cancer
Pfizer
Phase 3
1,068
Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou
2019-12-30
Active, closed
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals
Phase 2
515
Beijing, Tianjin, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Suzhou
2019-11-13
Active, closed
Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System
NCT04023370Iliac Artery Stenosis
Bentley InnoMed GmbH
Not applicable
182
Beijing, Shanghai, Suzhou, Tianjin, Wuhan, Zhejiang
2019-09-19
Active, closed
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359Dermatitis Atopic
Sanofi
Observational
1,860
Beijing, Changsha, Chongqing, Guangzhou, Harbin, Shanghai, Shenzhen, Suzhou
2019-08-15
Rows per page Showing 301–400 of 421
Previous 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/suzhou?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 421 of those studies with a site in Suzhou.

How many clinical trials are recruiting in Suzhou?

269 of the 421 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 53 have not yet opened recruitment, 87 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.